202917-18-8

Basic information

• Product Name: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel- (9CI)
• Synonyms: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel- (9CI);3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (αR,4S)-rel- (9CI);(alphaR,4S)-4-(4-Fluoro-2-hydroxyphenyl)-alpha-methyl-2,6-bis(1-methylethyl)-5-propyl-3-pyridinemethanol;glucagon receptor antagonists-2;3-PyridineMethanol, 4-(4-fluoro-2-hydroxyphenyl)-.alpha.-Methyl-2,6-bis(1-Methylethyl)-5-propyl-, (.alpha.R,4S)-rel- (9CI)
• CAS NO: 202917-18-8
• Molecular Formula: C22H32FNO2
• Molecular Weight: 361.498
• Mol File: 202917-18-8.mol

Chemical Properties

• Boiling Point: 469.6 °C at 760 mmHg
• Flash Point: 237.8 °C
• Appearance: /
• Density: 1.085
• PKA: 6.96±0.35(Predicted)
• CAS DataBase Reference: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel- (9CI)(202917-18-8)
• EPA Substance Registry System: 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel- (9CI)(202917-18-8)

Safety Data

• Hazardous Substances Data: 202917-18-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI) is used as a research compound for the development of new pharmaceuticals. Its specific chemical structure and properties make it a valuable tool in exploring its potential as a drug or drug intermediate.
Used in Drug Design and Synthesis:
In the field of medicinal chemistry, 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI) is utilized as a key building block in the design and synthesis of novel drug candidates. Its unique features, such as the pyridine ring and the 4-fluoro-2-hydroxyphenyl group, can be exploited to create new molecules with desired biological activities.
Used in Stereochemistry Studies:
The (aR,4S)-configuration of 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI) makes it an interesting subject for stereochemistry studies. Researchers can investigate the impact of stereochemistry on the compound's biological activity, selectivity, and pharmacokinetic properties, which can guide the development of more effective and safer drugs.
Used in Drug Discovery:
3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI) is employed in drug discovery processes to identify potential therapeutic agents. Its unique structure and properties can be assessed for various biological targets, such as enzymes, receptors, or ion channels, to find new treatments for diseases.
Used in Medicinal Chemistry Education:
3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-a-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI) can also be used as a teaching tool in medicinal chemistry courses, helping students understand the importance of stereochemistry, structural features, and functional groups in drug design and development. By studying 3-Pyridinemethanol, 4-(4-fluoro-2-hydroxyphenyl)-α-methyl-2,6-bis(1-methylethyl)-5-propyl-, (aR,4S)-rel(9CI), students can gain insights into the challenges and opportunities in the pharmaceutical industry.

Upstream product

• 470717-47-6 dimethyl 2,6-diisopropyl-4-(2'-benzyloxy-4'-fluoro-phenyl)-3,5-pyridinedicarboxylate 
• 470717-49-8 dimethyl 2,6-diisopropyl-4-hydroxy-3,5-pyridine-dicarboxylate 
• 503559-84-0 1-[4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-pyridin-3-yl]-ethanol 
• 618892-25-4 4-(2-benzyloxy-4-fluoro-phenyl)-5-formyl-2,6-diisopropyl-nicotinic acid methyl ester 
• 470717-52-3 dimethyl 2,6-diisopropyl-4-methoxy-3,5-pyridine-dicarboxylate 
• 470717-48-7 dimethyl 2,6-diisopropyl-4-oxo-2H-pyran-3,5-dicarboxylate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 503559-76-0 4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-nicotinic acid methyl ester 
• 618892-24-3 4-(2-benzyloxy-4-fluoro-phenyl)-5-hydroxymethyl-2,6-diisopropyl-nicotinic acid methyl ester 
• 503559-80-6 4-(2-Benzyloxy-4-fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-pyridine-3-carbaldehyde 

Relevant articles and documents

Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists

Optimized substituent patterns in 4-aryl-pyridine glucagon receptor antagonists were merged to produce highly potent derivatives containing both a 3-[(1R)-hydroxyethyl] and a 2′-hydroxy group. Due to restricted rotation of the phenyl-pyridine bond, these analogues exist as four isomers. A diastereoselective methylcopper reaction was developed to facilitate the synthesis, and single isomers were isolated with activities in the range IC50=10-25 nM.

Substituted biphenyls

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1aand R1bindependently represent (C1-C6) alkyl; R2represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4wherein R4is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.